Evogene Ltd. EVGN
Set alert
0.37 USD -0.01 -1.45%
At close · Oct 30
0.37 0.00 -0.40%
After hours · Oct 30, 4:00 PM ET
0.3653 Day range 0.3799
0.36 52-week range 1.26
- YTD
- -65.95%
- 1 year
- -69.54%
- Open
- 0.3775
- Prev close
- 0.3801
- Mkt cap
- 5.09M
- Vol
- 14.77K
- Avg vol
- 1.42M
- EPS
- -1.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3653
- High
- 0.3799
- Forward P/E
- -0.39
- Beta
- 1.08
- Short ratio
- 0.04
- Inst. own
- 11.12%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.87
- 200-d avg
- 4.76
- 1y target
- 8.13
2Y chart
Events in this range
- Nov 21, 2024Earnings: -1.31; estimate 0; surprise —%
Signals (87)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 7, 2026 | 3 months ago |
| RSI: Oversold | Jul 7, 2026 | 3 months ago |
| RSI: Oversold | Jun 16, 2026 | 4 months ago |
| RSI: Oversold | Jun 8, 2026 | 4 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 2, 2026 | 7 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 13, 2026 | 7 months ago |
| RSI: Oversold | Mar 6, 2026 | 8 months ago |
| RSI: Oversold | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 11, 2026 | 8 months ago |
| SMA: Bearish | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 4, 2026 | 9 months ago |
| MACD: Buy Signal | Feb 4, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 27, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 6, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 31, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 24, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 30, 2025 | 1 year ago |
| SMA: Bearish | Oct 23, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 6, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 16, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 12, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 14, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 5, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 17, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 24, 2025 | 1 year ago |
| SMA: Bullish | Jun 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 10, 2025 | 1 year ago |
| RSI: Overbought | Jun 10, 2025 | 1 year ago |
| MACD: Sell Signal | May 27, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 6, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 4, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 19, 2024 | 1 year ago |
| RSI: Oversold | Dec 10, 2024 | 1 year ago |
| RSI: Oversold | Nov 29, 2024 | 1 year ago |
Key statistics
- Market cap
- 9.17M
- Enterprise value
- 5.18M
- Trailing P/E
- 0.00
- Forward P/E
- -0.39
- PEG ratio
- 0.00
- Price / sales
- 0.97
- Price / book
- 0.57
- EPS (TTM)
- -4.46
- Beta
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -210.25%
- Revenue (TTM)
- 9.45M
- Revenue growth
- 39.80%
- Free cash flow
- -2.42M
- Total cash
- 20.91M
- Total debt
- 810.00K
- Return on equity
- -82.37%
- Shares outstanding
- 6.79M
- Short % of float
- 0.42%
- 50-day average
- 1.87
- 200-day average
- 4.76
Analyst view
Consensus: none
Price target (mean) 8.13 +2069.0% upside
Now 0.3746
- Target (low)
- 5.00
- Target (mean)
- 8.13
- Target (high)
- 11.25
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.725.
Financials — quick view
EVGN Revenue — quarterly 347.00K
EVGN Net income — quarterly -1.77M
EVGN EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 21, 2024 | Sep 1, 2024 | 0.00 | -1.31 | — | — |
| Aug 22, 2024 | Jun 1, 2024 | 0.00 | -1.06 | — | — |
| May 23, 2024 | Mar 1, 2024 | 0.00 | -0.80 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -1.40 | -1.30 | +0.10 | +7.14% |
| Nov 15, 2023 | Sep 1, 2023 | -1.70 | -0.80 | +0.90 | +52.94% |
| Aug 17, 2023 | Jun 1, 2023 | -1.90 | -1.70 | +0.20 | +10.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | Lake Street | main | Buy | Buy |
| Oct 2, 2023 | Alliance Global Partners | init | — | Buy |
| Aug 18, 2023 | Lake Street | main | Buy | Buy |
| Jul 21, 2023 | Roth MKM | main | Buy | Buy |
| May 2, 2023 | Lake Street | init | — | Buy |
| Sep 12, 2022 | Aegis Capital | main | — | Buy |
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- evogene.com
News
- Evogene Announces Acute Graft-Versus-Host Disease As Target Indication For Its Internal Drug Discovery Program
- Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
- Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
- Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Evogene Reaches Agreement With Pure Capital Group To Resolve Differences
- Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
- Critical Review: Evogene (NASDAQ:EVGN) vs. Allarity Therapeutics (NASDAQ:ALLR)
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Evogene Discloses That Another Nasdaq 180-Day Period For Regaining Minimum Bid Price Requirement Has Been Extended Until March 29, 2027
Your note
Sign in to keep a note on EVGN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SilverArc Capital Management, LLC | 0.61% | 308,550 | 416.54K | Mar 30, 2024 |
| Morgan Stanley | 0.06% | 28,404 | 38.34K | Mar 30, 2024 |
| BNP Paribas Financial Markets | 0.02% | 9,140 | 12.34K | Mar 30, 2024 |
| LPL Financial LLC | 0.01% | 6,684 | 9.02K | Mar 30, 2024 |
| JP Morgan Chase & Company | 0.01% | 3,943 | 5.32K | Mar 30, 2024 |
| UBS Group AG | 0.01% | 6,250 | 8.44K | Mar 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 5,901 | 7.97K | May 30, 2024 |